Added to YB: 2025-06-11
Pitch date: 2025-06-09
CHRS [bullish]
Coherus Oncology, Inc.
+58.82%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Market Cap
$96.2M
Pitch Price
$0.85
Price Target
7.50 (+456%)
Dividend
N/A
EV/EBITDA
-4.12
P/E
1.95
EV/Sales
1.15
Sector
Biotechnology
Category
value
Discounted Assets, Premium Potential: The Case for Coherus Oncology
CHRS: Trading at $0.80 (below $250M cash position), after transforming to pure oncology play. LOQTORZI (NPC immunotherapy) showing 200%+ YoY growth with expansion potential. Pipeline includes promising CCR8 antibody and IL-27 inhibitor. Debt-free, runway to 2027. 30% short interest could fuel squeeze. M&A target at fire-sale price vs $7.50 intrinsic value.
Read full article (5 min)